|Articles|June 1, 2018
- Pharmaceutical Executive-06-01-2018
- Volume 38
- Issue 6
Pharmaceutical Executive, June 2018 Issue (PDF)
Click the title above to open the Pharmaceutical Executive June 2018 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 7 years ago
US Maps Strategy to Reform Drug Pricingover 7 years ago
C-Suite Personality: Fit for Future?over 7 years ago
Insights for the Winover 7 years ago
Leveraging Lab Data in Advent of Personalized Marketingover 7 years ago
Asembia 2018: User-Friendly Urgencyover 7 years ago
Piecing Together the Pricing Puzzle: The Midterm Electionsover 7 years ago
Pharm Exec's Top 50 Companies 2018Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Lilly’s Orforglipron, Retatrutide Named as Defining GLP-1 Drugs of the Next Decade
2
Eli Lilly Enters $1.2 Billion Definitive Agreement to Acquire Ventyx Biosciences
3
FDA Limits Regulations on Non-Medical Grade Wearable Fitness Devices
4
FDA Sends Decision Letter to Vanda Pharmaceuticals for NDA of Hetlioz
5